Cost-effectiveness of monitoring endoxifen levels in breast cancer patients adjuvantly treated with tamoxifen.
Merel van NulandR A VremanR M T Ten HamA H M de Vries SchultinkH RosingJ H M SchellensJ H BeijnenA M HövelsPublished in: Breast cancer research and treatment (2018)
Based on this model, monitoring of endoxifen in adjuvant ERα + breast cancer patients treated with tamoxifen is likely to add QALYs and save costs from a healthcare payer perspective. We advise clinicians to consider integrating serum endoxifen concentration monitoring into standard adjuvant tamoxifen treatment of ERα + breast cancer patients.